Compounds for uses in pharmacological induction of HBF for treatment of sickle cell disease and ß-thalassemia

    公开(公告)号:US12246021B2

    公开(公告)日:2025-03-11

    申请号:US17439630

    申请日:2020-03-25

    Abstract: Provided herein are compounds of Formula (I). The compounds described herein are useful in treating a disease associated with the expression of endogenous embryonic/fetal globin (e.g., γ globin) in erythrocytes (e.g., treating β-thalassemia and/or sickle cell disease through at least the induction of the globin gene expression in erythrocytes), and/or anemia (β-thalassemia and/or sickle cell anemia). The compounds described herein are useful in treating, delaying, and/or preventing the adverse effects of β-thalassemia and/or sickle cell disease, inducing γ globin production, and/or inducing the expression of embryonic/fetal globin genes in a subject, cell, tissue, or biological sample. Also provided in the present disclosure are pharmaceutical compositions, kits, and methods of using the compounds for inducing γ globin production described herein and for treating any of the target diseases described herein.

    METHOD FOR PROMOTING GROWTH OF PLANTS
    5.
    发明公开

    公开(公告)号:US20240352477A1

    公开(公告)日:2024-10-24

    申请号:US18645166

    申请日:2024-04-24

    Abstract: The present invention relates to a method for promoting growth of plants. Particularly, the method of the present invention features overexpression of a calcineurin B-like (CBL) interacting protein kinase15 (CIPK15) having an isoleucine (Ile) residue at position 48 (e.g. a CIPK15 from rice) in plants which can promote growth of the plants. The present invention also relates to a recombinant construct comprising a nucleic acid encoding the CIPK15 operably linked to a promoter. The present invention further relates to a transgenic plant overexpressing the CIPK15 exhibiting improved growth compared to a non-transgenic plant counterpart.

Patent Agency Ranking